192 related articles for article (PubMed ID: 31130567)
1. Clinicopathological Significance and Diagnostic Value of DLEC1 Hypermethylation in Lung Cancer: A Meta-analysis.
Li X; Mao W; Guo D; Xu H
J Nippon Med Sch; 2019; 86(2):62-69. PubMed ID: 31130567
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S
Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160
[TBL] [Abstract][Full Text] [Related]
4. Association between GPX3 promoter methylation and malignant tumors: A meta-analysis.
Zhou C; Hu H; Zheng Z; Chen C; Li Y; Li B; Duan S
Pathol Res Pract; 2019 Jul; 215(7):152443. PubMed ID: 31085009
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of
Hu H; Li B; Zhou C; Ying X; Chen M; Huang T; Chen Y; Ji H; Pan R; Wang T; Jiang D; Chen Y; Yang Y; Duan S
Oncotarget; 2018 Jan; 9(4):5378-5386. PubMed ID: 29435185
[TBL] [Abstract][Full Text] [Related]
6. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
8. Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.
Pastuszak-Lewandoska D; Kordiak J; Antczak A; Migdalska-Sęk M; Czarnecka KH; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska-Senderowska D; Brzeziańska-Lasota E
Med Oncol; 2016 Jul; 33(7):75. PubMed ID: 27287342
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.
Zhang Q; Ying J; Li J; Fan Y; Poon FF; Ng KM; Tao Q; Jin J
J Urol; 2010 Aug; 184(2):731-7. PubMed ID: 20639048
[TBL] [Abstract][Full Text] [Related]
10. The high diagnostic accuracy of combined test of thyroid transcription factor 1 and Napsin A to distinguish between lung adenocarcinoma and squamous cell carcinoma: a meta-analysis.
Li L; Li X; Yin J; Song X; Chen X; Feng J; Gao H; Liu L; Wei S
PLoS One; 2014; 9(7):e100837. PubMed ID: 25003505
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.
Shen H; Che K; Cong L; Dong W; Zhang T; Liu Q; Du J
Oncotarget; 2017 May; 8(22):36812-36823. PubMed ID: 28415658
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of HE4 in lung cancer: a meta-analysis.
Cheng D; Sun Y; He H
Dis Markers; 2015; 2015():352670. PubMed ID: 25873748
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of circulating tumor cells for lung cancer: A systematic review and meta-analysis.
Ye Y; Li SL; Wang JJ; Liu B
Medicine (Baltimore); 2019 Mar; 98(12):e14936. PubMed ID: 30896658
[TBL] [Abstract][Full Text] [Related]
14. Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis.
Zhao ZH; Fan YC; Yang Y; Wang K
World J Gastroenterol; 2013 Nov; 19(41):7189-96. PubMed ID: 24222965
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
16. DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma.
Seven D; Yavuz E; Kilic E; Baltaci E; Karaman E; Ulutin T; Buyru N
Gene; 2015 May; 563(1):83-6. PubMed ID: 25746324
[TBL] [Abstract][Full Text] [Related]
17. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis.
Zhang B; Xie Z; Li B
Gene; 2019 Mar; 689():76-83. PubMed ID: 30552981
[TBL] [Abstract][Full Text] [Related]
20. Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-analysis.
Wang H; Qian J
J Cancer Res Ther; 2016 Dec; 12(Supplement):C260-C263. PubMed ID: 28230031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
